Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furoscix infusion duration safety study
NCT04161482Phase 1Completed
- Sponsor
- scPharmaceuticals Inc.
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of furosemide in heart failure (HF) (5 cohorts), sponsored by scPharmaceuticals Inc. Primary endpoint: Infusion Site Pain (11 Point Pain Scale) at 8 hours. Started Dec 2019; status: completed.
02
Drugs
furosemide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04161482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161482.